Sylvie Boyer

ORCID: 0000-0002-7567-5200
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • HIV/AIDS Research and Interventions
  • HIV, Drug Use, Sexual Risk
  • Hepatitis B Virus Studies
  • HIV/AIDS Impact and Responses
  • Adolescent Sexual and Reproductive Health
  • HIV Research and Treatment
  • Hepatitis C virus research
  • Global Maternal and Child Health
  • HIV/AIDS drug development and treatment
  • Liver Disease Diagnosis and Treatment
  • Hepatitis Viruses Studies and Epidemiology
  • Healthcare Systems and Reforms
  • Vaccine Coverage and Hesitancy
  • French Literature and Critical Theory
  • Healthcare Systems and Practices
  • HIV-related health complications and treatments
  • Cultural Insights and Digital Impacts
  • Viral Infections and Outbreaks Research
  • Diverse Cultural and Historical Studies
  • French Urban and Social Studies
  • Pneumocystis jirovecii pneumonia detection and treatment
  • dental development and anomalies
  • Dental Radiography and Imaging
  • Linguistics and Discourse Analysis
  • Oral microbiology and periodontitis research

Inserm
2016-2025

Institut de Recherche pour le Développement
2016-2025

Economic & Social Sciences, Health Systems & Medical Informatics
2016-2025

Aix-Marseille Université
2012-2024

Central Hospital of Yaoundé
2011-2024

Université de Montpellier
2011-2023

Agropolis International
2023

Université de Dschang
2023

Université Paris Cité
2005-2023

Hôpital Émile-Roux
2023

An efavirenz-based regimen (with a 600-mg dose of efavirenz, known as EFV600) was the World Health Organization preferred first-line treatment for human immunodeficiency virus type 1 (HIV-1) infection until June 2018. Given concerns about side effects, dolutegravir-based and low-dose efavirenz–based combinations have been considered treatments HIV-1 in resource-limited settings.

10.1056/nejmoa1904340 article EN New England Journal of Medicine 2019-07-24

10.1016/s2352-3018(20)30238-1 article EN The Lancet HIV 2020-09-30

Antiretroviral therapy (ART) suppresses HIV viral load in all body compartments and so limits the risk of transmission. It has been suggested that ART not only contributes to preventing transmission at individual but potentially also population level. This trial aims evaluate effect initiated immediately after identification/diagnosis HIV-infected individuals, regardless CD4 count, on incidence surrounding population. The primary outcome overall will be over two years. Secondary outcomes...

10.1186/1745-6215-14-230 article EN cc-by Trials 2013-01-01
Solène M. Laville Cécile Couchoud Marc Bauwens Henri Vacher-Coponat Gabriel Choukroun and 95 more Sophie Liabeuf Nadia Honoré Sabrina Boime Emilie Gardeur-Algros François Chantrel Xabina Larre Karen Leffoné Mathilde Prezelin‐Reydit Eric Cellarier Patricia Girault A. Tiple Aurélie Caillet Damiano Ceruasuolo Clémence Béchade Sophie Roche Anaïs Tenon-Franzin Abdelkader Bemrah Muriel Siebert Sahar Bayat Cécile Vigneau M Naudin Jean‐Michel Halimi Bénédicte Sautenet Anne-Lise Varnier Gwendoline Arnoult Aurore Wolak Isabelle Kazès Ghizlane Izaaryene Franck Mazoué Adeline Crémades Stéphanie Gentile Philippe Brunet Caroline Savet Maxime Desmaret Cécile Courivaud Cécilia Citadelle Janetta Jacqueline Deloumeaux Valérie Galantine Devi Rochemont Mamadou Khali Sow Mathieu Nacher Blandine Wurtz Hélène Marini Stéphane Edet Evelyne Ducamp Zoubair Cherquaoui Hayet Baouche Houssem Eddine Tebbakh Jean‐Philippe Jaïs Lucile Mercadal la Pitié Hôpitalde Mohamed Belkacemi Yohan Duny Mélanie Martin Jean‐Pierre Daurès Olivier Moranne Florence Glaudet A. Vergnenègre Fatouma Touré Marie-Rita Monzel Véronique Vogel Marie‐Line Erpelding Philippe Melchior Amandine Ziegler Emmanuelle Laurain Aurélie Bideau Sylvie Merle Alex Ranlin Violaine Schmitt Catherine Marimoutou Henri Vacher Coponat Sophie Lapalu Ludivine Brun Benoît Lepage Nathalie Longlune Sébastien Gomis C. Foulon Marc Hazzan François Glowacki Noémie Baroux Jean-Michel Tivollier Assia Hami Jean Xavier Lemauft Jean‐Michel Nguyen Frédéric Lavainne Julien Hogan Amélie Joly Ayman Sarraj Fabien Duthé Bénédicte Ayrault Marc Bauwens Marie Hélène Pierron Pascale Testevuide Sylvie Boyer A. Albaladejo Meroño

Clinical trials of direct oral anticoagulants (DOAC) are scarce and inconclusive in patients who receiving dialysis, for whom DOAC not labelled Europe. In a French nationwide registry study on chronic we compared the effectiveness safety off-label use vs approved vitamin K antagonist (VKA).

10.1093/ndt/gfae042 article EN cc-by-nc Nephrology Dialysis Transplantation 2024-02-15
Christian Laurent Bintou Dembélé Keïta Issifou Yaya Gwenvael Le Guicher Luis Sagaon‐Teyssier and 86 more Mawuényégan Kouamivi Agboyibor Alou Coulibaly Issa Traoré Jean-Baptiste Malan Irith De Baetselier August Eubanks Lucas Riegel Daniela Rojas Castro H Faye-Ketté A. Koné Souba Diandé Claver Anoumou Dagnra Laetitia Serrano Fodié Diallo Ephrem Mensah Ter Tiero Elias Dah Camille Anoma Béa Vuylsteke Bruno Spire Christian Laurent Issifou Yaya Sayouba Ouédraogo Bruno Granouillac Gwenvael Le Guicher Laetitia Serrano Martine Peeters Clotilde Couderc Bruno Spire Luis Sagaon‐Teyssier Marion Mora Gwenaëlle Maradan Michel Bourrelly Mohamed Mimi Cyril Bérenger Sylvie Boyer Daniela Rojas Castro Lucas Riegel Paméla Palvadeau Béa Vuylsteke Irith De Baetselier Thijs Reyniers Bintou Dembélé Keïta Fodié Diallo Alou Coulibaly A Maïga Drissa Camara Mahamadou Diarra Aly Ouologuem Naboh Sangaré Abdoul Aziz Keita Oumar Cissé Fodé Amara Traoré Bréhima Abdrahamane Ouary Ibrahima Kanta Camille Anoma Jean-Baptiste Malan Rachelle Kotchi Niamkey Thomas Aka Kpassou Julien Lokrou Noufo Hamed Coulibaly Ekissi Jean Armel Koffi Dibi Frédéric N’guessan Stéphane‐Alain Babo Yoro Adama Cissé Ter Tiero Elias Dah Issa Traoré Camille Rajaonarivelo Fayçal Rodrique Ouedraogo Joseph Ouedraogo Christian Coulibaly Mamadou Ouedraogo Ousseni Ilboudo Abdoulazziz Traoré Honoré Comsiambo Ephrem Mensah Mawuényégan Kouamivi Agboyibor Anani Attisso Anouwarsadat Kokouba Aléda Mawuli Badjassim Kouakou Kokouvi Selom Agbomadji Messan Attiogbe Kossi Jeff Yaka Agbégnigan Lorette Ekon Julien Bimba Claver Anoumou Dagnra Kokou Dominique Tegueni

10.1016/s2352-3018(21)00005-9 article EN publisher-specific-oa The Lancet HIV 2021-05-25

The independent evaluation of the Cameroonian antiretroviral therapy (ART) Programme, which reached one highest coverage in eligible HIV-infected population (58%) Sub-Saharan Africa, offered opportunity to assess ART outcomes context decentralization HIV care delivery.A cross-sectional survey (EVAL, ANRS 12-116, 2007) was carried out a random sample 3151 HIV-positive patients (response rate 90%) attending 27 treatment centres at different level healthcare delivery (central, provincial and...

10.1097/01.aids.0000366078.45451.46 article EN AIDS 2009-12-17

Prompt uptake of antiretroviral treatment (ART) is essential to ensure the success universal test and treat (UTT) strategies prevent HIV transmission in high-prevalence settings. We describe ART initiation rates associated factors within an ongoing UTT cluster-randomized trial rural South Africa. HIV-positive individuals were offered immediate intervention arm vs. national guidelines recommended (CD4≤350 cells/mm(3)) control arm. used data collected up July 2015 among ART-eligible linked...

10.1080/09540121.2016.1164808 article EN cc-by AIDS Care 2016-06-02

Expanding health insurance is viewed as a core strategy for achieving universal coverage. In Senegal, in many other developing countries, this has been implemented by creating community-based (CBHI) schemes with voluntary enrolment and fixed premium paid enrollees. Yet little known about how the individuals' experience of CBHI further influences their willingness to pay (WTP). paper, we test existence reinforcement effect between effective WTP analysing mutual relationship. We rely on...

10.1136/bmjph-2024-001636 article EN cc-by-nc BMJ Public Health 2025-01-01

Introduction Mother-to-child transmission (MTCT) of HIV, syphilis, and hepatitis B virus (HBV) commonly observed in the WHO African region is associated with excess morbidity mortality. Despite some progress, coverage interventions to prevent MTCT these infections remains insufficient, particularly for syphilis HBV. To fulfil gaps achieve triple elimination by 2030, World Health Organization (WHO) advocates integration prevention (PMTCT) activities HBV HIV antenatal services. In partnership...

10.1101/2025.03.27.25324811 preprint EN cc-by medRxiv (Cold Spring Harbor Laboratory) 2025-03-28

Seventy-six compounds of biological interest for the diagnosis inherited disorders amino acids (AA) metabolism have previously been demonstrated to be detectable in positive mode electrospray ionisation tandem mass spectrometry (ESI-MS/MS), after separation by ion-pairing reversed-phase liquid chromatography (RPLC). The method used tridecafluoroheptanoic acid as agent, and a gradient acetonitrile elution most retained compounds. This had suitable qualitative many AA disorders, quantitative...

10.1002/rcm.2197 article EN Rapid Communications in Mass Spectrometry 2005-10-18

Objective To assess the extent to which user fees for antiretroviral therapy (ART) represent a financial barrier access ART among HIV-positive patients in Yaoundé, Cameroon.Methods Sociodemographic, economic and clinical data were collected from random sample of 707 followed up six public hospitals capital city (Yaoundé) its surroundings through face-to-face interviews carried out by trained interviewers independently medical staff questionnaires filled prescribing physicians.Logistic...

10.2471/blt.07.049643 article EN cc-by Bulletin of the World Health Organization 2009-04-01

Summary Objective To identify correlates of self‐reported antiretroviral therapies (ART) interruptions among people living with HIV and AIDS (PLWHA) in Cameroon. Methods Analyses were based on data collected the national survey EVAL (ANRS 12‐116) 533 ART‐treated PLWHA Yaoundé, capital city Cameroon, its neighbourhood. Logistic regression models used to factors associated ART longer than two consecutive days during previous 4 weeks. Results reported by 68 patients (12.8%). After adjustment...

10.1111/j.1365-3156.2008.02170.x article EN Tropical Medicine & International Health 2008-11-05

Objectives The emergence of HIV drug resistance is a crucial issue in A frica, where second‐line antiretroviral therapy ( ART ) limited, expensive and complex. We assessed the association between adherence patterns over time, using an measure that distinguishes low from treatment interruptions, rural C ameroon. Methods performed cohort study among patients receiving nonnucleoside reverse transcriptase inhibitor NNRTI )‐based nine district hospitals, data S tratall trial (2006−2010)....

10.1111/hiv.12140 article EN HIV Medicine 2014-03-03

Evidence of gender differences in antiretroviral treatment (ART) outcomes sub-Saharan Africa is conflicting. Our objective was to assess (1) adherence ART and (2) virologic failure, immune reconstitution, mortality, disease progression adjusting for adherence.

10.1097/qai.0000000000000604 article EN JAIDS Journal of Acquired Immune Deficiency Syndromes 2015-03-18

To document patients' and healthcare professionals' (HCP) experiences with hepatitis B virus (HBV) C (HCV) diagnosis care, as well consequences of these infections on life trajectories in Cameroon, an endemic country sub-Saharan Africa.Qualitative sociological study combining in-depth interviews observations medical consultations. Interviews transcripts were thematically analysed according to the following themes: circumstances perceptions surrounding screening, counselling disclosure,...

10.1136/bmjopen-2018-025415 article EN cc-by-nc BMJ Open 2019-03-01

Background: Intimate partner violence in its various forms increases HIV exposure female victims and potentially jeopardizes the treatment cascade, for instance, by impeding engagement adherence to care. Elevated rates of intimate are reported Central Africa. Evidence on effect antiviral therapy interruption is lacking Cameroon, where only 330,000 women live with 19% HIV-positive people virally suppressed. This study aimed assess prevalence factors against relationship antiretroviral ⩾1...

10.1177/1745506519848546 article EN cc-by-nc Women s Health 2019-01-01
Christian Laurent Issifou Yaya Benjamin Cuer Luis Sagaon‐Teyssier Ephrem Mensah and 82 more Ter Tiero Elias Dah Alou Coulibaly Malan Jean-Baptiste Kouamé Gilles Peytavin Laetitia Serrano August Eubanks Issa Traoré Fodié Diallo Lucas Riegel Daniela Rojas Castro Claver Anoumou Dagnra Camille Anoma Béa Vuylsteke Bintou Dembélé Keïta Bruno Spire Christian Laurent Issifou Yaya Sayouba Ouédraogo Bruno Granouillac Benjamin Cuer Laetitia Serrano Martine Peeters Clotilde Couderc Bruno Spire Luis Sagaon‐Teyssier Marion Mora Gwenaëlle Maradan Michel Bourrelly Cyril Bérenger Sylvie Boyer Daniela Rojas Castro Lucas Riegel Paméla Palvadeau Béa Vuylsteke Irith De Baetselier Thijs Reyniers Bintou Dembélé Keïta Fodié Diallo Alou Coulibaly A Maïga Drissa Camara M. Diarra Aly Ouologuem Naboh Sangaré Abdoul Aziz Keita Oumar Cissé Fodé Amara Traoré Bréhima Abdrahamane Ouary Ibrahima Kanta Bakary Coulibaly Camille Anoma Malan Jean-Baptiste Kouamé Rachelle Kotchi Niamkey Thomas Aka Kpassou Julien Lokrou Noufo Hamed Coulibaly Ekessi Jean Armel Koffi Dibi Frédéric N’guessan Stéphane‐Alain Babo Yoro Adama Cissé Ter Tiero Elias Dah Issa Traoré Camille Rajaonarivelo Fayçal Rodrique Ouedraogo Joseph Ouedraogo Christian Coulibaly Mamadou Ouedraogo Ousseni Ilboudo Abdoulazziz Traoré Honoré Comsiambo Ephrem Mensah Mawuényégan Kouamivi Agboyibor Anani Attisso Anouwarsadat Kokouba Aléda Mawuli Badjassim Kouakou Kokouvi Selom Agbomadji Messan Attiogbe Kossi Jeff Yaka Agbégnigan Lorette Ekon Julien Bimba Claver Anoumou Dagnra Kokou Dominique Tegueni

Abstract Background Data on human immunodeficiency virus (HIV) seroconversion among men who have sex with (MSM) using pre-exposure prophylaxis (PrEP) in West Africa are needed. This study aimed to document HIV and associated determinants, PrEP adherence, plasma drug concentrations, resistance MSM event-driven or daily Burkina Faso, Côte d’Ivoire, Mali, Togo. Methods A prospective cohort was conducted 2017–2021 HIV-seronegative aged 18 over were at high risk of infection. Participants could...

10.1093/cid/ciad221 article EN Clinical Infectious Diseases 2023-04-13
Coming Soon ...